New drug used in lethal injection for execution in US

Image
ANI Florida [U.S.A.]
Last Updated : Aug 25 2017 | 5:13 AM IST

A convict here has been executed using a drug in lethal injection that has never been used in the United States.

Fifty-three-old Mark Asay was reportedly executed using etomidate as one of three drugs in the lethal injection. This is the first time etomidate has been used in execution.

Etomidate substituted midazolam, a drug that has become harder to get because some drug manufacturers don't want it used in executions.

Etomidate, an intravenous anesthetic, was invented by scientists from Janssen Pharmaceuticals in the 1960s, CNN quoted Greg Panico, a spokesman for the company, as saying.

This month, the Florida Supreme Court rejected arguments from Asay's attorneys that the new drug would cause too much pain, according to WJAX. The state's highest court turned down a motion to block the execution, saying the inmate had not shown it would lead to more pain.

Asay was convicted in 1988 of the racially motivated murders of two men in Jacksonville the previous year.

A jury found him guilty of killing Robert Lee Booker -- who was black -- and Robert McDowell. Before he shot Booker, he called him a racial epithet, according to CNN affiliate WJAX.

Prosecutors say he killed McDowell, who was dressed as a woman, after saying he would pay him for sex, the station reported.

The execution marks Florida's first since a US Supreme Court ruling temporarily halted the practice in early 2016, saying the state's sentencing process was unconstitutional because it gave judges, rather than juries, too much power in deciding whether to execute an inmate, reported CNN.

The US Supreme Court on Thursday had denied a stay of execution request for Asay, and was scheduled to die by injection after 6 p.m. ET. Asay had no other pending petitions with the Supreme Court.

Mark James Asay was the first white man to be put to death in Florida for killing a black man since the state reinstituted the death penalty in 1979.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 25 2017 | 5:05 AM IST

Next Story